Tufts model estimates 82x ROI and up to $21 million in value from Medable AI agent

Tufts Center for the Study of Drug Development (CSDD) and clinical trial platform company Medable recently announced an analysis estimating that Medable’s Clinical Monitoring Agent could deliver an 82x return on investment for phase 3 trials and 64x for phase 2. Based on expected net present value (eNPV), that equated to roughly $21 million in… The post Tufts model estimates 82x ROI and up to $21…